AZ/MSD’s Lynparza assigned Orphan status in US

17th October 2018 Uncategorised 0

AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.

More: AZ/MSD’s Lynparza assigned Orphan status in US
Source: News